Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024 |
| 22 Jan 2025 |
| Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference | 3 Jan 2025 |
| Genmab to Hold 2024 R&D Update and ASH Data Review Meeting | 11 Dec 2024 |